Oral selenium supplementation has no effect on prostate-specific antigen velocity in men undergoing active surveillance for localized prostate cancer

Cancer Prevention Research

Volumn 3, Issue 8, 2010, Pages 1035-1043

  Stratton, M Suzanne ^a   Algotar, Amit M ^a   Ranger Moore, James ^a   Stratton, Steven P ^a   Slate, Elizabeth H ^b   Hsu, Chiu Hsieh ^a   Thompson, Patricia A ^a   Clark, Larry C ^a   Ahmann, Frederick R ^a  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; PLACEBO; PROSTATE SPECIFIC ANTIGEN; SELENIUM;

ADULT; AGED; ARTICLE; BODY MASS; BREATH ANALYSIS; CANCER GROWTH; CANCER LOCALIZATION; CATARACT; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG SAFETY; DRUG WITHDRAWAL; GLAUCOMA; GLEASON SCORE; HAIR DISEASE; HUMAN; KIDNEY DISEASE; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAIL DISEASE; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SIDE EFFECT; SMOKING; STATISTICAL SIGNIFICANCE; SUPPLEMENTATION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VELOCITY;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; CARCINOMA; DIETARY SUPPLEMENTS; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; HUMANS; MALE; MIDDLE AGED; PLACEBOS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SELENIUM;

EID: 77955437772     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-09-0143     Document Type: Article

References (28)

1. ACS. Cancer facts and figures 2009. Atlanta: American Cancer Society; 2009.
2. Fowler FJ, Jr., Barry MJ, Lu-Yao G, Roman A, Wasson J, Wennberg JE. Patient-reported complications and follow-up treatment after radical prostatectomy. The National Medicare Experience: 1988-1990 (updated June 1993). Urology 1993;42:622-9.
3. Potosky AL, Legler J, Albertsen PC, et al. Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes Study. J Natl Cancer Inst 2000;92:1582-92.
4. Eisenberger M, Partin A. Progress toward identifying aggressive prostate cancer. N Engl J Med 2004;351:180-1.
5. Carter HB, Sauvageot J, Walsh PC, Epstein JI. Prospective evaluation of men with stage T1C adenocarcinoma of the prostate. J Urol 1997;157:2206-9.
6. Kakehi Y, Kamoto T, Shiraishi T, et al. Correlation of initial PSA level and biopsy features with PSA-doubling time in early stage prostate cancers in Japanese men. Eur Urol 2002;41:47-53.
7. Kattan MW, Eastham JA, Wheeler TM, et al. Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol 2003;170:1792-7.
8. Chodak GW, Warren KS. Watchful waiting for prostate cancer: a review article. Prostate Cancer Prostatic Dis 2006;9:25-9.
9. Klotz L. Active surveillance for prostate cancer: for whom? J Clin Oncol 2005;23:8165-9.
10. Messing EM, Thompson I, Jr. Follow-up of conservatively managed prostate cancer: watchful waiting and primary hormonal therapy. Urol Clin North Am 2003;30:687-702, viii.
11. Nelson MA, Reid M, Duffield-Lillico AJ, Marshall JR. Prostate cancer and selenium. Urol Clin North Am 2002;29:67-70.
12. Moyad M. Complementary medicine in urology. Urol Clin North Am 2002;29:XV.
13. Stratton MS, Reid ME, Schwartzberg G, et al. Selenium and inhibition of disease progression in men diagnosed with prostate carcinoma: study design and baseline characteristics of the "Watchful Waiting" Study. Anticancer Drugs 2003;14:595-600.
14. Thompson IM. Chemoprevention of prostate cancer: agents and study designs. J Urol 2007;178:S9-13.
15. Clark LC, Combs GF, Jr., Turnbull BW, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 1996;276:1957-63.
16. Duffield-Lillico AJ, Dalkin BL, Reid ME, et al. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU Int 2003;91:608-12.
17. Lippman SM, Goodman PJ, Klein EA, et al. Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). J Natl Cancer Inst 2005;97:94-102.
18. Lippman SM, Klein EA, Goodman PJ, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2009;301:39-51.
19. Reid ME, Stratton MS, Lillico AJ, et al. A report of high-dose selenium supplementation: response and toxicities. J Trace Elem Med Biol 2004;18:69-74.
20. NIH. Dietary supplement fact sheet: selenium. Dietary supplements fact sheet 2003 8/1/2004 [cited 2008 05/09/2008]. Available from: http://ods.od.nih.gov/factsheets/selenium.asp.
21. Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics 1982;38:963-74.
22. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004;363:157-63.
23. Yang GQ, Wang SZ, Zhou RH, Sun SZ. Endemic selenium intoxication of humans in China. Am J Clin Nutr 1983;37:872-81.
24. NIH State-of-the-Science Conference Statement on Multivitamin/Mineral Supplements and Chronic Disease Prevention. NIH Consens State Sci Statements 2006;23:1-30.
25. FDA CfVM. Selenium regulations finalized. CVM update 1997 08/27/97 [cited 2008 09/05/08]. Available from: http://www.fda.gov/cvm/CVM-Updates/selenium. html.
26. Bleys J, Navas-Acien A, Guallar E. Serum selenium levels and allcause, cancer, and cardiovascular mortality among U.S. adults. Arch Intern Med 2008;168:404-10.
27. Holmberg L, Bill-Axelson A, Helgesen F, et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 2002;347:781-9.
28. Duffield-Lillico AJ, Slate EH, Reid ME, et al. Selenium supplementation and secondary prevention of nonmelanoma skin cancer in a randomized trial. J Natl Cancer Inst 2003;95:1477-81.